Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Paying For Cures Requires Bigger Budgets, Not Lower Drug Prices – Execs

Executive Summary

Payors need to adopt a longer-term focus on coverage policies for prescription drugs and biologics that recognizes the benefits of covering high-priced, but often curative, treatments like those for hepatitis C, panelists argue at AEI-sponsored event.


Related Content

Medicare Part D Cost Trends: A Good News/Bad News Story For Biopharma
Time Is Now For Shaping CMS Drug Affordability, Innovation Policies – Slavitt
Amortized Payments For High-Cost Drugs Won't Work, Insurer CEOs Say
The Sovaldi Anniversary? Burgess Wants Part D Milestone To Change How Gov’t Values Rx Spending


Related Companies